EcoDrugPlus

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSPREG00000017599
Gene Symbol: LOC103457823
2 Cross references
252 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSPREG00000017033
Gene Symbol: CHRM2
3 Cross references
185 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPREG00000002050
Gene Symbol: CHRM3
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPREG00000010661
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSPREG00000017969
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSPREG00000019987
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPREG00000004896
Gene Symbol: CHRNA3
3 Cross references
201 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSPREG00000006599
Gene Symbol: CHRNA7
3 Cross references
205 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPREG00000016997
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSPREG00000004877
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSPREG00000022325
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSPREG00000003916
Gene Symbol: F2R
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).